CSPC says NMPA accepts NDA for anbenitamab, albumin-bound docetaxel neoadjuvant breast cancer combo under priority review

• CSPC said China’s NMPA accepted an NDA for anbenitamab (KN026) with its albumin-bound docetaxel (HB1801) for neoadjuvant HER2-positive breast cancer.
• The filing entered the NMPA’s priority review pathway.
• Anbenitamab is co-developed with Jiangsu Alphamab Oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12271412), on August 04, 2026, and is solely responsible for the information contained therein.